Advanced Alzheimer’s Drug Trial Updates

A new two-part clinical trial is preparing to test TRTL-913, a potential new oral medication for tinnitus. This Phase 2a study plans to enroll 100 participants and marks a methodical step in determining whether this compound is safe for people and if it can reduce the perception of chronic ringing or buzzing in the ears.

A Study in Two Distinct Phases

The trial’s design is split into Part A and Part B, each with a clear objective. Part A is a randomized, double-blind, placebo-controlled study. It will involve healthy adult volunteers who will receive TRTL-913 or a placebo for seven days. The primary goals here are to assess the drug’s safety, tolerability, and pharmacokinetics—how the body absorbs, distributes, and eliminates the compound. This initial phase is standard practice; it establishes a baseline safety profile before testing in the target patient population.

Part B is an open-label, multiple ascending dose study. It will enroll adults who experience tinnitus. In this part, all participants will receive TRTL-913 for a two-week treatment course. Researchers will monitor for safety and, critically, begin to measure efficacy. They will look for changes in the severity and impact of participants’ tinnitus symptoms.

Who Can Participate in the Trial?

The eligibility criteria differ for each part. For Part A with healthy volunteers, participants must be adults aged 18 to 64 (with a potential older cohort of 65-80), have a body mass index between 18 and 35, and be in good general health as confirmed by medical exams and tests like an electrocardiogram.

Part B is for adults with tinnitus. While the full inclusion and exclusion criteria for this group are detailed on ClinicalTrials.gov, the core requirement is a documented diagnosis of tinnitus. The study aims to include a broad age range from 18 to 80 years old. Common exclusions in such trials typically involve other severe medical conditions, certain medications, or hearing loss from specific causes that could confound the results.

The Search for a Pharmacological Treatment

Tinnitus affects millions of people worldwide, yet there are no drugs specifically approved by regulatory agencies like the U.S. FDA to treat the core symptom. Current management often relies on sound therapy, counseling, and hearing aids, which help people cope but do not directly eliminate the perceived sound. The development of TRTL-913 represents an ongoing effort to find a safe and effective pharmacological treatment that can directly modulate the neurological activity believed to underlie chronic tinnitus.

While the exact mechanism of action of TRTL-913 is proprietary, it is part of a class of research investigating targeted neuromodulation. The compound’s progression to a Phase 2a trial indicates it has passed initial safety hurdles in earlier studies.

Current Status and Patient Implications

As of the latest update, this trial is listed as NOT_YET_RECRUITING. This status means the study protocol is finalized and approved, but the sites are not yet actively screening or enrolling participants. Individuals interested in this research should monitor its official listing on ClinicalTrials.gov (Identifier: NCT07777549) for status changes to “RECRUITING” or “ENROLLING_BY_INVITATION.” The study aims to enroll approximately 100 participants across its two parts.

The outcome of this trial will provide essential data. Positive results from Part B would signal that TRTL-913 warrants larger, more definitive Phase 3 trials. For the field of hearing health, a successful treatment could introduce a new option into the clinical toolkit. For patients, it represents a point of hope in a research area where progress, while steady, has been slow and challenging.

This article is for informational purposes only. Consult a qualified professional for personalised advice.

Source:
A Study of the Safety and Efficacy of TRTL-913 in Healthy Volunteers (Part A) and in Adults With Tinnitus (Part B) (ClinicalTrials.gov: NCT07777549)